BMY vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 12, 2026
BMY
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BMY | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 9.8619 | 18.315 | BMY |
| PEG Ratio | 2.4058 | 91.5346 | BMY |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.7% | 5.3% | BMY |
| Earnings Growth | 153.1% | -69.5% | BMY |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 33.8/100 | 39.1/100 | GSK |
| Profit Margin | 18.9% | 14.5% | BMY |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | SELL | SELL | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BMY
NeutralMixed signals - no dominant trend phase, RSI 42
GSK
MarkdownPrice below a falling SMA50 (slope -0.9%), weak momentum, RSI 35
Fundamentals Snapshot
| Metric | BMY | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 9.7 | 9.7 |
| Trailing P/E | 14.0 | 15.1 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.1% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.3% | 0.3% |
| EPS | 4.54 | 3.19 |
| Dividend Yield | 0.04% | 0.04% |